Nihal Bakeer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nihal Bakeer has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Brian Michael Feldman
The Hospital for Sick Children Toronto Ontario Canada
2 shared publications Cindy Bailey
Orthopaedic Haemophilia Treatment Centre at Orthopaedic Institute for Children Los Angeles Los Angeles California USA
2 shared publicationsOlympia Papakonstantinou
National and Kapodistrian University of Athens, “Attikon” Hospital Chaidari Athens Greece
2 shared publicationsPaul Babyn
Department of Medical Imaging University of Saskatchewan College of Medicine Saskatoon Saskatchewan Canada
2 shared publications- Saunya Dover
Child Health Evaluative Sciences The Hospital for Sick Children Research Institute Toronto ON Canada
2 shared publications Sridhar Gibikote
Department of Radiology Christian Medical College Vellore India
2 shared publications
Latest Publications
- 18 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (3) , 862-864
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
- 18 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (3) , 862-864
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
- 5 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (S3) , 120-127
Haemophilic arthropathy: Diagnosis, management, and aging patient considerations
Gene therapy and universal use of safer, more effective, and personalised prophylactic regimens (factor, and nonfactor) are expected to prevent joint bleeding and promote joint health in persons with haemophilia (PwH). Growing evidence suggests that subclinical bleeding, with active and inactive synovial proliferation, continues and haemophilic arthropathy remains a major morbidity in PwH despite early institution of joint prophylaxis. Joint health assessment is evolving with physical examination scores complementing imaging scores. Point‐of‐care ultrasound is emerging as a safe, cost‐effective, and readily available tool for acute determination of musculoskeletal abnormalities, serial evaluation of joints for sonographic markers of haemophilic arthropathy, and in providing objective insight into the efficacy of new therapies. In acute haemarthrosis, arthrocentesis expedites recovery and prevent the vicious cycle of bleed‐synovitis‐rebleed. When synovial proliferation develops, a multidisciplinary team approach is critical with haematology, orthopaedics, and physiotherapy involvement. Synovectomy is considered for patients with chronic synovitis that fail conservative management. Non‐surgical and minimally invasive procedures should always be offered and considered first. Careful patient selection, screening and early intervention increase the success of these interventions in reducing bleeding, pain, and improving joint function and quality of life. Chemical synovectomy is practical in developing countries, but radioactive synovectomy appears to be more effective. When surgical synovectomy is considered, arthroscopic/minimally invasive approach should be attempted first. In advanced haemophilic arthropathy, joint replacement and arthrodesis can be considered. While excited about the future of haemophilia management, navigating musculoskeletal challenges in the aging haemophilia population is equally important.
- 5 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (S3) , 120-127
Haemophilic arthropathy: Diagnosis, management, and aging patient considerations
Gene therapy and universal use of safer, more effective, and personalised prophylactic regimens (factor, and nonfactor) are expected to prevent joint bleeding and promote joint health in persons with haemophilia (PwH). Growing evidence suggests that subclinical bleeding, with active and inactive synovial proliferation, continues and haemophilic arthropathy remains a major morbidity in PwH despite early institution of joint prophylaxis. Joint health assessment is evolving with physical examination scores complementing imaging scores. Point‐of‐care ultrasound is emerging as a safe, cost‐effective, and readily available tool for acute determination of musculoskeletal abnormalities, serial evaluation of joints for sonographic markers of haemophilic arthropathy, and in providing objective insight into the efficacy of new therapies. In acute haemarthrosis, arthrocentesis expedites recovery and prevent the vicious cycle of bleed‐synovitis‐rebleed. When synovial proliferation develops, a multidisciplinary team approach is critical with haematology, orthopaedics, and physiotherapy involvement. Synovectomy is considered for patients with chronic synovitis that fail conservative management. Non‐surgical and minimally invasive procedures should always be offered and considered first. Careful patient selection, screening and early intervention increase the success of these interventions in reducing bleeding, pain, and improving joint function and quality of life. Chemical synovectomy is practical in developing countries, but radioactive synovectomy appears to be more effective. When surgical synovectomy is considered, arthroscopic/minimally invasive approach should be attempted first. In advanced haemophilic arthropathy, joint replacement and arthrodesis can be considered. While excited about the future of haemophilia management, navigating musculoskeletal challenges in the aging haemophilia population is equally important.
- 19 January 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 141, 118-132
Consensus-Based Evaluation of Outcome Measures in Pediatric Stroke Care: A Toolkit
- 19 January 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 141, 118-132
Consensus-Based Evaluation of Outcome Measures in Pediatric Stroke Care: A Toolkit
- Top Cited PapersOpen Access
- 26 March 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (2) , e12690
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
- 26 March 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (2) , e12690
Top Cited PapersOpen AccessThe Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
- Open Access
- 10 July 2021
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (5) , e12531
Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting
- 10 July 2021
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (5) , e12531
Open AccessMusculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting
- Open Access
- 27 November 2020
- Published by Wiley in Haemophilia
- Vol. 27 (1) , 90-99
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US
Introduction Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX. Management of patients undergoing surgery while receiving emicizumab is of clinical interest due to paucity of data. Aim Review real‐world experience of PwHA with/without FVIII inhibitors who required surgery while receiving emicizumab prophylaxis. Methods Data regarding peri‐operative management, including type of surgery, haemostatic agent use and bleeding complications, were collected for PwHA receiving emicizumab undergoing surgery between 25/10/18 and 31/12/19 at the Indiana Hemophilia and Thrombosis Center. Analyses were exploratory and descriptive. Results Twenty minor and five major surgeries were performed in 17 and five patients, respectively. Overall, 9/20 minor surgeries were planned to occur with emicizumab as the sole haemostatic agent; of these, four required additional coagulation factor (2 due to haematomas following port removals, 1 due to oozing at port removal site, 1 due to bleeding following squamous cell carcinoma removal). Three of the 11 minor surgeries with planned additional coagulation factor resulted in non‐major bleeds; all were safely managed with additional coagulation factor. All five major surgeries were planned with additional haemostatic agents; there was 1 bleed in a patient undergoing elbow synovectomy with nerve transposition, likely triggered by physical/occupational therapy. There were no major bleeds, thrombotic events or deaths. Conclusions Additional haemostatic agent use is safe in PwHA undergoing surgery while receiving emicizumab. Additional data are needed to determine the optimal dosing/length of treatment of additional haemostatic agents to lower bleeding risk.
- 27 November 2020
- Published by Wiley in Haemophilia
- Vol. 27 (1) , 90-99
Open AccessManagement of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US
Introduction Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX. Management of patients undergoing surgery while receiving emicizumab is of clinical interest due to paucity of data. Aim Review real‐world experience of PwHA with/without FVIII inhibitors who required surgery while receiving emicizumab prophylaxis. Methods Data regarding peri‐operative management, including type of surgery, haemostatic agent use and bleeding complications, were collected for PwHA receiving emicizumab undergoing surgery between 25/10/18 and 31/12/19 at the Indiana Hemophilia and Thrombosis Center. Analyses were exploratory and descriptive. Results Twenty minor and five major surgeries were performed in 17 and five patients, respectively. Overall, 9/20 minor surgeries were planned to occur with emicizumab as the sole haemostatic agent; of these, four required additional coagulation factor (2 due to haematomas following port removals, 1 due to oozing at port removal site, 1 due to bleeding following squamous cell carcinoma removal). Three of the 11 minor surgeries with planned additional coagulation factor resulted in non‐major bleeds; all were safely managed with additional coagulation factor. All five major surgeries were planned with additional haemostatic agents; there was 1 bleed in a patient undergoing elbow synovectomy with nerve transposition, likely triggered by physical/occupational therapy. There were no major bleeds, thrombotic events or deaths. Conclusions Additional haemostatic agent use is safe in PwHA undergoing surgery while receiving emicizumab. Additional data are needed to determine the optimal dosing/length of treatment of additional haemostatic agents to lower bleeding risk.
- 19 July 2017
- Published by Wiley in Haemophilia
- Vol. 23 (4) , 491-493
A new wave in the evaluation of haemophilic arthropathy
- 19 July 2017
- Published by Wiley in Haemophilia
- Vol. 23 (4) , 491-493
A new wave in the evaluation of haemophilic arthropathy